Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F Baker

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Cancer Research|April 6, 2001
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growthM E Tome, A F Baker, G Powis, et al.
Journal of in Vitro Fertilization and Embryo Transfer : IVF|June 1, 1990
Serum progestagen-associated endometrial protein (PEP) levels in conception versus nonconception cycles following in vitro fertilization-embryo transferJ H Check, K Nowroozi, J S Chase, et al.
Leukemia|July 21, 2006
Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndromeA F Baker, W Bellamy, W R Tate, et al.
Archives of Andrology|January 1, 1995
Cumulus removal and addition of follicular fluid possibly improves pregnancy rates with in vitro fertilization for male factorC L Hourani, J H Check, A F Baker, et al.
Investigational New Drugs|June 20, 2012
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancersA F Baker, K N Adab, N Raghunand, et al.
Cancer Chemotherapy and Pharmacology|June 19, 2014
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)T Dragovich, D Laheru, F Dayyani, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cancer Research|April 6, 2001
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growthM E Tome, A F Baker, G Powis, et al.
Journal of in Vitro Fertilization and Embryo Transfer : IVF|June 1, 1990
Serum progestagen-associated endometrial protein (PEP) levels in conception versus nonconception cycles following in vitro fertilization-embryo transferJ H Check, K Nowroozi, J S Chase, et al.
Leukemia|July 21, 2006
Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndromeA F Baker, W Bellamy, W R Tate, et al.
Archives of Andrology|January 1, 1995
Cumulus removal and addition of follicular fluid possibly improves pregnancy rates with in vitro fertilization for male factorC L Hourani, J H Check, A F Baker, et al.
Investigational New Drugs|June 20, 2012
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancersA F Baker, K N Adab, N Raghunand, et al.
Cancer Chemotherapy and Pharmacology|June 19, 2014
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)T Dragovich, D Laheru, F Dayyani, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Pageof 2